Our results do not preclude a pathogenic role of serum anti-AQP4 Ab in NMO but underline the requirement of additional factors to allow peripheral Abs to cross the blood-brain barrier (BBB) and gain their targets in the CNS. The gene discussed is AQP4; the disease is neuromyelitis optica.